IACH News of the week

IACH News of the Week, curated by Dr Edwin Uriel Suárez , is a weekly summary of the latest advancements and discoveries in the field of hematology compiled in an easy-to-digest format. It highlights research breakthroughs, clinical trial results, interesting case studies, and important health advisories – all within the last week. This is a valuable tool for medical professionals with limited time to stay up-to-date on the ever-evolving world of hematology.

News of the Week– May 8, 2025 (CLICK TO VIEW)

  • Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis [Retrospective cohort].
  • Molecular monitoring versus standard clinical care in younger adults with acute myeloid leukaemia: results from the UK NCRI AML17 and AML19 randomised, controlled, phase 3 trials.
  • Updated recommendations for the management of hepatitis B, C, and E virus infections in patients with haematological malignancies and those undergoing haematopoietic cell transplantation: recommendations from the 9th European Conference on Infections in Leukaemia (ECIL-9) [Consensus].
  • Treatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients An Official American Thoracic Society Clinical Practice Guideline.

  • European guidelines on treatment and supportive measures in chronic neutropenias: A consensus between the European Hematology Association and the EuNet‐INNOCHRON COST Action based on a systematic evidence review.

News of the Week– April 28, 2025 (CLICK TO VIEW)

  • Characterization of the phenotypic consequences of the Duffy-null genotype [Retrospective study]
  • Venetoclax schedule in AML: 7 vs. 14 vs. 21 vs. 28 days [Editorial]
  • Updated Definition and Scoring of Disseminated Intravascular Coagulation in 2025: Communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation [Consensus]
  • What is radiation-induced acute myeloid leukemia/can it be accurately identified? [Perspective]
  • Genetic subtypes of B-cell acute lymphoblastic leukemia in adults [Review]

News of the Week– April 17, 2025 (CLICK TO VIEW)

  • Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis [Chronic Malignancies Working Party Session]
  • The Phase 2 STARGAZE Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort  [Presidential Symposium]
  • EBMT consensus on allogeneic transplantation in T-cell lymphoma [Lymphoma Working Party Session]
  • Role of allo-HCT in ‘non-classical’ MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT [Chronic Malignancies Working Party Session]
  • Update on the recommendations of the 10th European Conference on Infections in Leukaemia (ECIL) [Infectious Diseases Working Party Session]

News of the Month– April 7, 2025 (CLICK TO VIEW)

  • Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study [clinical trial]
  • Role of Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia in the Contemporary Era [Review]
  • Trends in allogeneic transplantation for favorable risk acute myeloid leukemia in first remission: a longitudinal study of >15 years from the ALWP of the EBMT [Retrospective study]
  • Optimal timing and impact of allogeneic peripheral blood stem cell transplantation in adult T-cell lymphoblastic lymphoma: insights from a large cohort multi-center real-world study in Shanghai [Retrospective study]
  • Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation [Observational Study] 
  • Autologous hematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT [Guidelines] 
  • Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations [Retrospective Study]
  • Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases [Letter to the Editor]
  • Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT [Clinical Trial]
  • Allogeneic Stem Cell Transplantation in Participants With Hematologic Malignancies Following Pembrolizumab Therapy [Retrospective study]
  • Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma [Letter to the Editor]

News of the Week– March 23, 2025 (CLICK TO VIEW)

  • Ruxolitinib combined with dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis patients in China [Phase 2 clinical trial]
  • Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy [Retrospective study].
  • Itacitinib for the Prevention of IEC Therapy–Associated CRS: Results From the Two-Part Phase 2 INCB 39110-211 Study.
  • Enterocolitis associated with glofitamab—First report and clinicopathological findings in three cases.
  • Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management [Review].

News of the Week– March 16, 2025 (CLICK TO VIEW)

  • BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement [Retrospective study]
  • Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera [Retrospective study].
  • Efficacy of Combined CD38 and PD1 Inhibition with Isatuximab and Cemiplimab in Relapsed/Refractory NK/T-Cell Lymphoma [Phase II trial]
  • Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL

News of the Week– March 11, 2025 (CLICK TO VIEW)

  • Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma Therapies [Retrospective study].
  • Methylation sequencing enhances the interpretation of clonal hematopoiesis dynamics [Basic research: Letter to the Editor].
  • Role of azathioprine in the management of ITP in the TPO-RA era: a single-center retrospective study. 
  • Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial [Clinical trial].
  • Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia [Review Series]

News of the Week– March 2, 2025 (CLICK TO VIEW)

  • Co-occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma [Systematic review].
  • Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry [Retrospective study].
  • Genomic landscape of testicular follicular lymphoma is characterized by frequent 1p36/TNFRSF14 alterations [Case series].
  • Serum free light chains in a racially diverse population including African Americans and populations from South Africa [Retrospective study].
  • How I treat iron-refractory iron deficiency anemia—An expert opinion-based treatment guidance for children and adults [Review]

News of the Month– February 26, 2025 (CLICK TO VIEW)

  • Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma [observational study]
  • Utility of the 2024 best practice recommendations from the EBMT Cellular Therapy and Immunobiology Working Party for use of donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation [Correspondence].Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation [Letter to the editor].
  • Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide [Retrospective study].
  • UK consensus statement on the use of plerixafor in healthy stem cell donors  [Letter to the editor].
  • Measurable residual disease as predictor of post–day +100 relapses after allografting in adult AML [Retrospective Study]
  • Clearance of Driver Mutations after Transplantation for Myelofibrosis [Retrospective study]. 
  • Pre-Transplant MRD Does Not Seem to Impact Survival in NPM1-Mutated AML Undergoing Allogeneic Stem Cell Transplantation [Retrospective Study]
  • aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection [Clinical Application]
  • Safety and efficacy of the ROCK-2-inhibitor Belumosudil in cGvHD treatment – a retrospective, German-Swiss multicenter real-world data analysis [Retrospective Cohort]
  • Hematopoietic cell transplantation soon after first relapse in acute myeloid leukemia [Pros and Cons Editorial].
  • A phase 2 multicenter trial of ruxolitinib to treat bronchiolitis obliterans syndrome after allogeneic HCT [Clinical trial].

News of the Week– February 23, 2025 (CLICK TO VIEW)

  • Zanubrutinib for the treatment of Bing–Neel syndrome [Case series].
  • How I treat patients who are refractory to platelet transfusions [Review].
  • Diagnosis, management, and outcomes of drug-induced erythrocytosis: A systematic review.
  • Clinically relevant bleeding according to location of metastases in cancer-associated thrombosis [Retrospective study].
  • Clinical-genomic profiling of MDS to inform allo-HSCT: Recommendations from an international panel on behalf of the EBMT

News of the Week– February 16, 2025 (CLICK TO VIEW)

  • Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia [Phase 1 clinical trial].
  • Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study [clinical trial].
  • VITT-like Monoclonal Gammopathy of Thrombotic Significance [Case series].
  • CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma [Case series].

  • European Myeloma Network Group Review and Consensus Statement on Primary Plasma Cell Leukemia [Guidelines].

News of the Week– February 10, 2025 (CLICK TO VIEW)

  • Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma [Retrospective study].
  • Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia [Phase 3 clinical trial].
  • CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 [Case report].
  • Hemophagocytic Lymphohistiocytosis [Review].

News of the Week– February 4, 2025 (CLICK TO VIEW)

  • Risk of hospitalization with infection in adults with primary AIHA treated with rituximab: a French nationwide study [Retrospective study].  
  • How I treat iron overload in adult MDS [Review].
  • International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma [Consensus].
  • Prognostic impact of expression of CD2, CD25, and/or CD30 in/on mast cells in systemic mastocytosis: a registry study of the European Competence Network on Mastocytosis [Retrospective study].  
  • Prospective Pharmacokinetic Evaluation of Venetoclax in AML Supports Re-Evaluation of Recommended Dose Adjustments With Azole Antifungals [Prospective study].

News of the Week– January 27, 2025 (CLICK TO VIEW)

  • How We Treat Anemia in Myelofibrosis [Review].
  • Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation [Phase 2b clinical trial].  
  • Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone Induction in Newly Diagnosed Myeloma: Analysis of the MIDAS Trial [Phase III clinical trial].
  • JAK1/2 inhibitor ruxolitinib for treating systemic chronic active Epstein-Barr virus disease  [Phase 2 clinical trial]. 
  • Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia [Phase 2 clinical trial].  

News of the Week– January 20, 2025 (CLICK TO VIEW)

  • AML typical mutations (CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular [Retrospective study].
  • Hypomethylating agents for patients with VEXAS without myelodysplastic syndrome: Clinical outcome and longitudinal follow-up of vacuolization and UBA1 clonal dynamics [Case series].
  • Surrogate endpoints in mature B-cell neoplasms – meaningful or misleading? [Perspective].
  • The Heterogeneous Syndrome of Noninfectious Causes of Persistent Fever in Neutropenic Patients With Hematologic Malignancy: Another Opportunity for Stewardship? [Commentary].  
  • How I Treat Higher-Risk MDS [Review].

News of the Month– January 15, 2025 (CLICK TO VIEW)

  • Decision analysis for transplant candidates with primary myelofibrosis in the ruxolitinib era [decision analysis study]
  • Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome  [Letter to the editor].
  • Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis [Retrospective observational study].
  • Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT [Retrospective study].
  • Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study [Clinical Trial].
  • Novel machine learning technique further clarifies unrelated donor selection to optimize transplantation outcomes [Retrospective Study].
  • A systematic review and meta-analysis of  HHV-6 and mortality after hematopoietic cell transplant
  • High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas [Clinical Trial].
  • Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism [Retrospective Study].
  • Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party study [Retrospective study].
  • Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis [Retrospective Study].
  • Artificial intelligence enabled interpretation of ECG images to predict hematopoietic cell transplantation toxicity. [Retrospective Study].
  • Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation [Retrospective Study].
  • Autologous stem cell transplantation for multiple patients whose myeloma-defining event was SLiM [Retrospective study].

News of the Week– January 13, 2025 (CLICK TO VIEW)

  • Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma [Clinical trial].
  • Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma [Clinical trial].
  • Clearance of Driver Mutations after Transplantation for Myelofibrosis [Retrospective study].
  • T cell malignancies after CAR T cell therapy in the DESCAR-T registry [Retrospective study].
  • Diagnosis and management of monoclonal gammopathy of renal significance: A British Society for Haematology good practice paper [Guideline].

News of the Week– January 6, 2025 (CLICK TO VIEW)

  • Primary Large B-cell Lymphomas of Immune-Privileged Sites [Review]
  • How I Treat Sickle Cell Disease with Gene Therapy [Review]
  • Integration of Clinical Outcomes and Molecular Features in Extramedullary Disease in Multiple Myeloma [Retrospective Study]

  • Identification of Factors Predicting Low-Risk Febrile Neutropenia Admissions in Adults with Acute Myeloid Leukemia [Retrospective Study]

News of the Week– December 30, 2024 (CLICK TO VIEW)

  • The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma [Retrospective study].
  • Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration [Retrospective study].  
  • Efficacy and Safety of Venetoclax Plus Azacitidine for Patients With Treatment-Naive High-Risk Myelodysplastic Syndromes [Phase 1 clinical trial].  
  • Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms [Retrospective study].
  • The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study [Retrospective study].

News of the Week– December 16, 2024 (CLICK TO VIEW)

  • Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
  • Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs. Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial.
  •  Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study.  
  • Ibrutinib-Rituximab Is Superior to Rituximab-Chemotherapy in Previously Untreated Older Mantle Cell Lymphoma Patients: Results from the International Randomised Controlled Trial, Enrich.
  • Lack of Benefit of Autologous Hematopoietic Cell Transplantation (auto-HCT) in Mantle Cell Lymphoma (MCL) Patients (pts) in First Complete Remission (CR) with Undetectable Minimal Residual Disease (uMRD): Initial Report from the ECOG-ACRIN EA4151 Phase 3 Randomized Trial.
  • Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase 3 Study (inMIND).
  • Updated Results and Longer Follow-up from the AUGMENT-101 Phase 2 Study of Revumenib in All Patients with Relapsed or Refractory (R/R) KMT2Ar Acute Leukemia.
  • Long-Term Response Analysis of Transfusion Independence in Erythropoiesis Stimulating Agent–Naive Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes Treated with Luspatercept Vs. Epoetin Alfa in the COMMANDS Trial.
  • Extended Treatment of Venous Thromboembolism with Reduced- Vs. Full-Dose Direct Oral Anticoagulants in Patients at High Risk of Recurrence.
  • Identification of Hepatic-like Erythropoietin with Enhanced Activity As a New Cause of Hereditary and Acquired Erythrocytosis.  

News of the Month– December 6, 2024 (CLICK TO VIEW)

  • The Role of Pre-existing Anti-HLA Antibodies in Severe Aplastic Anemia Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation [Retrospective study].
  • Autologous Hematopoietic Cell Transplantation Consolidation for First Response is Associated with Longer Survival Among Patients with Nodal Peripheral T Cell Lymphoma [Retrospective study].  
  • Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma after salvage autologous hematopoietic stem-cell transplantation [(Myeloma XII [ACCoRD]): interim analysis of a multicenter, open-label, randomized, phase 3 trial].
  • Induction prior autologous hematopoietic cell transplantation in multiple myeloma [Review].
  • Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation [Retrospective study].  
  • ASTCT and USCLC Clinical Practice Recommendations for Allogeneic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome [Guideline]. 
  • Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation [Retrospective study].
  • Best Practice Considerations by The American Society of Transplant and Cellular Therapy: Infection Prevention and Management After Chimeric Antigen Receptor T Cell Therapy for Hematological Malignancies [Guideline].  
  • Interplay between donor age and HLA-DP matching in 10/10 HLA-matched unrelated donor HCT [Retrospective study].
  • Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma [Retrospective study].
  • Long-term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium [Retrospective study].
  • Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation [Systematic review and meta-analysis].

News of the Week – December 2, 2024 (CLICK TO VIEW)

  • Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study [Phase 2 clinical trial].
  • Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia [Phase 1b–2 clinical trial].
  • Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial [Phase 3 clinical trial].
  • Acute Leukemias of Ambiguous Lineage With MDS-Associated Mutations Show Similar Prognosis Compared to Acute Myeloid Leukemia With MDS-Associated Mutations: A Study From the Bone Marrow Pathology Group [Retrospective study].
  • Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms [Retrospective study].
  • Delaying pegaspargase during induction in adults with acute lymphoblastic leukaemia is associated with lower risk of high-grade hepatotoxicity without adversely impacting outcomes [Retrospective study].

  • Development of hyperdiploidy starts at an early age and takes a decade to complete [Basic research].

News of the Week – November 25, 2024 (CLICK TO VIEW)

  • Retreatment of Multiple Myeloma with Previously Refractory Drugs [Retrospective study].
  • Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry [Retrospective study].
  • How I approach the treatment of thrombotic complications in patients with myeloproliferative neoplasms [Review].
  • JAK2-mutant clonal hematopoiesis is associated with venous thromboembolism [Retrospective study]. 
  • Prevention and Treatment of Cancer-Related Infections, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology [Guideline].

News of the Week – November 17, 2024 (CLICK TO VIEW)

  • Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT [Descriptive study]
  • Comparison of EasyM, a clonotypic mass spectrometry assay, and EuroFlow minimal residual disease assessment in multiple myeloma [Retrospective study]
  • Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review [Systematic review]
  • Ruxolitinib-based regimen in children with autoimmune or autoinflammatory disease-related haemophagocytic lymphohistiocytosis [Retrospective study]
  • Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma [News drug-regulation]
  • FDA-approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [News drug regulation]

News of the Week – November 10, 2024 (CLICK TO VIEW)

  • A modern view of LGL leukemia [Review]
  • Risk prediction for clonal cytopenia: multicenter real-world evidence [Retrospective study]
  • The use of direct oral anticoagulants in the secondary prevention of venous thromboembolism in patients with severe thrombophilia: communication from the ISTH SSC Subcommittee on Physiological Anticoagulants and Thrombophilia [Narrative review]
  • Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical Hodgkin lymphoma: A British Society for Haematology Good Practice Paper [Guideline]
  • Acute Promyelocytic Leukemia: Long-Term Outcomes from the HARMONY Project [Retrospective study]

News of the Week – November 3, 2024 (CLICK TO VIEW)

  • Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma [Clinical trial]
  • Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis [Consensus]
  • Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 study  [Clinical trial]
  • Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation [Clinical trial]
  • Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma [Retrospective and basic research study]
  • Intensive chemotherapy after hypomethylating agent and venetoclax in adult acute myeloid leukemia [Retrospective study]

News of the Month – October 29, 2024 (CLICK TO VIEW)

  • Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML [Clinical trial]
  • Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study [Clinical trial]
  • Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD [Retrospective study]
  • Long-Term Follow-Up of the Prospective Randomized AATT Study (Autologous or Allogeneic Transplantation in Patients With Peripheral T-Cell Lymphoma) [Prospective study]
  • Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (PCNSL) Undergoing Autologous Hematopoietic Cell Transplantation (Auto-HCT) [Retrospective study]
  • Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Adults Over 70 Years Old [Review]
  • ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies [Consensus]
  • High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT [Retrospective study]
  • Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines from the American Society for Transplantation and Cellular Therapy [Guidelines]
  • Late cytomegalovirus disease after hematopoietic cell transplantation: significance of novel transplantation techniques
  • CMV reactivation during pre transplantation evaluation: a novel risk factor for post transplantation CMV reactivation [Retrospective study]
  • CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute graft versus host disease [Basic and clinical research]
  • Transplant for myelodysplastic neoplasms [Retrospective study]
  • Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission [Retrospective study]

News of the Week – October 27, 2024 (CLICK TO VIEW)

  • Nivolumab + AVD in Advanced-Stage Classic Hodgkin’s Lymphoma [Phase 3 clinical trial]
  • Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL [Retrospective study]
  • Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma [Retrospective study]
  • Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality [Systematic review and meta-analysis]
  • How I Treat Older Patients with Relapsed/ Refractory Diffuse Large B Cell Lymphoma [Review article]

News of the Week – October 20, 2024 (CLICK TO VIEW)

  • Histiocytosis of the orbit and its association with KRAS mutations [Retrospective study]
  • Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL [Retrospective study]
  • How I Treat: Maintenance Therapy in Acute Myeloid Leukemia [Review]
  • How I treat Blastic Plasmacytoid Dendritic Cell Neoplasm [Review]
  • Hairy-Cell Leukemia [Review]

News of the Week – October 13, 2024 (CLICK TO VIEW)

  • Aggressive Lymphoma after CD19 CAR T-Cell Therapy [Case report]
  • Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma [Retrospective study]
  • Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange [Retrospective study]
  • Febrile Neutropenia in Patients with Duffy-null Associated Neutrophil Counts and Multiple Myeloma or AL amyloidosis [Retrospective study]
  • How I diagnose and treat cardiorespiratory complications of transfusion [Review]

News of the Week – October 6, 2024 (CLICK TO VIEW)

  • Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis [Retrospective study]
  • Intrathecal chemotherapy as treatment for chimeric antigen receptor T cell (CAR T) therapy associated neurotoxicity [Retrospective study]
  • PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis [Retrospective study]
  • Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial [Clinical trial]
  • Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B

News of the Week – September 29, 2024 (CLICK TO VIEW)

  • Venetoclax plus decitabine as a bridge to allogeneic hematopoietic stem-cell transplantation in older patients with acute myeloid leukemia (VEN-DEC GITMO): final report of a multicenter, single-arm, phase 2 trial [Clinical trial]
  • Risk of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis [Retrospective study]
  • Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia [Clinical trial]  
  • Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML [Retrospective study]
  • Transformation of marginal zone lymphoma to Hodgkin lymphoma [Case series study]
  • Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation [Basic and prospective research]
  • Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma [Retrospective study]
  • Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease [Clinical trial] 

News of the Week – September 15, 2024 (CLICK TO VIEW)

  • Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial
  • TP53 Mutated Acute Myeloid Leukemia: How Can We Improve Outcomes?
  • Advanced imaging for earlier diagnosis and morbidity prevention in multiple myeloma: A British Society of Haematology and UK Myeloma Society Good Practice Paper
  • Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

News of the Week – September 8, 2024 (CLICK TO VIEW)

  • Risk Stratification in Older Intensively Treated Patients With AML
  • Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy
  • Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma
  • Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
  • Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

News of the Month – September 4, 2024 (CLICK TO VIEW)

  • Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Adult Acute Myeloid Leukemia
  • How risky is a second allogeneic stem cell transplantation?
  • Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Adults with Acute Promyelocytic Leukemia
  • Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors
  • Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
  • PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT
  • Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT
  • Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBMT
  • Human Leukocyte Antigen Mismatching and Survival in Contemporary Hematopoietic Cell Transplantation for Hematologic Malignancies
  • Transplantation in Adult Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis: Yes or No?
  • Melphalan Dose in Combination with Fludarabine Affects GI Toxicity and GVHD after Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes
  • A Multicenter Phase II Trial of Ruxolitinib for Treatment of Corticosteroid Refractory Sclerotic Chronic Graft-Versus-Host Disease
  • Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim
  • First-line treatment of severe aplastic anemia: immunosuppressive therapy plus eltrombopag versus haploidentical hematopoietic stem cell transplantation, a multicenter prospective study
  • Early Toxicity and Efficacy of Four Different Conditioning Regimens for Autologous Hematopoietic Cell Transplantation in Patients With Lymphoma: Impact of Drug Shortages in a Resource-Constrained Country

News of the Month – August 2, 2024 (CLICK TO VIEW)

  • Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies.
  • Post-transplant cyclophosphamide compared to sirolimus/ tacrolimus in reduced intensity conditioning transplants.
  • Cyclophosphamide and thiotepa increases risk of transplant-associated thrombotic microangiopathy.
  • Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma.
  • An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease.
  • Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasms (t-MN) After Autologous Transplant for Hodgkin Lymphoma (HL).
  • Clonal relapse dynamics in acute myeloid leukemia (AML) following allogeneic hematopoietic cell transplantation (alloHCT).
  • Alternative donor transplantation for severe aplastic anemia (SAA): a comparative study of the SAAWP EBMT.
  • Continuously improving outcome over time after second allogeneic stem cell transplantation (alloSCT2) in relapsed acute myeloid leukemia (AML): an EBMT registry analysis of 1540 patients.
  • Combination of anti-thymocyte globulin (ATG) with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis in patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT): systematic review and meta-analysis.
  • Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients In The Maintenance Era: Real-world Results From The Canadian Myeloma Research Group Database.
  • Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?
  • Abatacept for acute graft-versus-host disease prophylaxis after unrelated donor hematopoietic cell transplantation (HCT).
  • Assessing the efficacy of allogeneic hematopoietic cell transplantation (Allo-HCT) in VEXAS syndrome: results of a systematic review and meta-analysis.

News of the Week – July 28, 2024 (CLICK TO VIEW)

  • E1910 trial: Blinatumomab for measurable residual disease (MRD)-negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in adults.
  • Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.
  • Optimizing the Post-CAR T Monitoring Period for Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel.
  • Clinical Outcomes After Idecabtagene Vicleucel in Older Multiple Myeloma Patients: A Multicenter Real-world Experience.
  • How I (Diagnose and) Treat Myeloid / Lymphoid Neoplasms (MLN) with Tyrosine Kinase (TK) Gene Fusions.

News of the Week – July 21, 2024 (CLICK TO VIEW)

  • CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) for large B-cell lymphomas (LBCL) progressing after CD19-directed CAR T-cell therapy (CAR19): a dose-finding phase 1 study.
  • Improved prevention and treatment strategies for differentiation syndrome (DS) contribute to reducing early mortality in patients with acute promyelocytic leukemia (APL): a clinical trial.
  • Response-Adapted Ultralow-Dose Radiation Therapy (RT) for Orbital Indolent B-Cell Lymphoma (BCL): A Phase 2 Nonrandomized Controlled Trial.
  • An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone (ICD) in patients with newly diagnosed POEMS syndrome.
  • The origin of ferritin reference intervals: a systematic review.

News of the Week – July 14, 2024 (CLICK TO VIEW)

  • Clinical trial in advanced-stage classical Hodgkin lymphoma (HL): BrECADD versus eBEACOPP.
  • Low-Dose Planned Glucarpidase Allows Safe Outpatient High-Dose Methotrexate (HD-MTX )Treatment for central nervous system (CNS) Lymphoma. A prospective nonrandomized study.
  • Mitral regurgitation (MR) is associated with similar loss of von Willebrand factor (VWF) large multimers, but lower frequency of anemia compared with aortic stenosis (AS).
  • A systematic review and meta-analysis of nonrelapse mortality (NRM) after chimeric antigen receptor (CAR) T-cell therapy.
  • How I Treat: Differentiation Therapy in Acute Myeloid Leukemia (AML).

News of the Week – July 7, 2024 (CLICK TO VIEW)

  • Venetoclax and hypomethylating (VEN-HMA) agents in octogenarians and nonagenarians with acute myeloid leukemia (AML).
  • Efficacy and safety of bendamustine‐containing bridging therapy (BT) in relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) patients receiving CD19 chimeric antigen receptor (CAR) T-cells.
  • Molecular diagnosis of primary CNS lymphoma (PCNSL) in 2024 using MYD88Leu²⁶⁵Pro and IL-10.
  • Response and resistance to menin inhibitor in upstream binding transcription factor (UBTF-TD) acute myeloid leukemia (AML).
  • Pembrolizumab and low-dose, single-fraction radiotherapy (RT) for patients with relapsed or refractory multiple myeloma (RRMM).

News of the Month- July 4, 2024 (CLICK TO VIEW)

  • Post-transplant cyclophosphamide (PTCy) at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin (ATG) in haploidentical transplantation (Haplo-HCT) with myeloablative conditioning (MAC).
  • Younger unrelated donors may be preferable over HLA match in the post-transplant cyclophosphamide (PTCy) era: a study from the ALWP of the EBMT.
  • Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation.
  • How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.
  • Yttrium-90 Anti-CD25-BEAM-Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Peripheral T Cell Lymphoma (PTCL).
  • Vedolizumab for the prevention of intestinal acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT): a randomized phase 3 trial.
  • Evaluation of European LeukemiaNet (ELN) 2022 risk classification in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HCT) for acute myeloid leukemia (AML): Identification of a very poor prognosis genetic group.
  • Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia (T-ALL): a registry-based study by the EBMT acute leukemia working party.
  • Anti-thymocyte globulin (ATG) or post-transplant cyclophosphamide to prevent graft-versus-host disease (GVHD) in matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (allo-HSCT)?
  • Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation (AlloSCT): The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
  • Racial/ethnic disparities in availability of volunteer unrelated donors for allogeneic stem cell transplantation (AlloSCT).
  • Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM).
  • Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma (PCNSL): results of Alliance 51101.
  • Graft Failure (GF) Incidence, Risk Factors, and Outcomes in Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (AlloSCT) Using Post-Transplant Cyclophosphamide (PTCy).

News of the Week – June 30, 2024 (CLICK TO VIEW)

  • Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma (RRMM).
  • Brigatinib in Anaplastic lymphoma kinase (ALK)–positive anaplastic large-cell lymphoma (ALCL) after Failure of Brentuximab Vedotin
  • Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1).
  • Risk of second tumors and T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy.
  • Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia (ET).
  • Serum mass spectrometry for treatment monitoring in patients with relapsed/refractory multiple myeloma (RRMM) receiving chimeric antigen receptor (CAR) T-cells.

News of the Week – June 23, 2024 (CLICK TO VIEW)

  • Phase 3 study (IMROZ) results of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) versus VRD for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM)
  • Glofitamab (CD20:CD3 bispecific antibody) plus gemcitabine and oxaliplatin (Glofit-GemOx) versus Rituximab(R)-GemOx for Relapsed/Refractory (R/R) Difusse Large B-Cell Lymphoma (DLBCL): results of a global randomized phase III trial (STARGLO)
  • First results of the APOLLO trial: a randomized phase III study to compare arsenic trioxide (ATO) plus all-trans retinoic acid (ATRA [arm A]) versus standard ATRA plus Idarubicin (AIDA regimen [arm B]) for patients with newly diagnosed, high-risk acute promyelocytic leukemia (HR-APL)
  • ENERGIZE: a global phase 3 double-blind, randomized, placebo-controlled study of mitapivat demonstrating efficacy and safety in adults with alpha- or beta-non-transfusion-dependent thalassemia (α- or β-NTDT)
  • Asciminib (ASC) provides superior efficacy and excellent safety and tolerability versus tyrosine kinase inhibitors (TKI) in newly diagnosed chronic myeloid leukemia (ND-CML) in the pivotal ASC4FIRST study
  • The landscape of TP53 mutations and their prognostic impact in Chronic Lymphocytic Leukemia (CLL)
  • Acalabrutinib (acala) plus bendamustine and rituximab (BR) in untreated mantle cell lymphoma (MCL): results from the phase 3, double-blind, placebo-controlled ECHO trial
  • Guidelines session: EHA-ESMO Clinical Practice Guideline on primary central nervous system lymphoma (PCNSL)

News of the Month – June 7, 2024 (CLICK TO VIEW)

  • Abstract number: e1901. Evolving patterns of transplant strategies for mantle cell lymphoma in the era of BTK inhibitors and CAR-T therapy
  • Abstract number: 7073. Survival outcomes after autologous stem cell transplantation in T follicular helper type lymphoma
  • Abstract number: e19043. Survival benefit of autologous transplant (ASCT) for mantle cell lymphoma (MCL) in the California Cancer Registry (CCR)
  • Abstract number: e1903. Relapsed Hodgkin lymphoma autologous stem cell transplant long term follow up
  • Abstract number: 7032. Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
  • Donor lymphocyte infusion (DLI) after allogeneic hematopoietic cell transplantation (allo-HCT) for hematological malignancies.
  • From 50th Annual Meeting of the EBMT
  • Fecal microbiota transplantation for high-risk treatment-naïve acute graft-versus-host disease (GVHD)
  • Peripheral blood (PB) stem cell versus bone marrow (BM) graft in reduced intensity conditioning (RIC) haploidentical hematopoietic stem cell transplantation (Haplo-SCT) for acute myeloid leukemia (AML) in complete remission (CR)
  • Improved outcome of allogeneic transplantation (AlloSCT) in older patients treated for myeloid malignancies using post-transplantation cyclophosphamide (PTCy) and reduced duration of immune suppression
  • Efficacy of autologous (AutoSCT) and allogeneic hematopoietic cell transplantation (AlloSCT) in adults with acute promyelocytic leukemia (APL)

News of the Week – June 2, 2024 (CLICK TO VIEW)

  • Oral azacitidine in patients with relapsed or refractory follicular helper T-cell lymphoma
  • Risk stratification in Waldenström macroglobulinemia
  • VEXAS syndrome and thrombosis
  • Tattoos as a risk factor for malignant lymphoma
  • Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor (CAR)-T cell therapy in clinical practice for relapsed and refractory multiple myeloma

News of the Week – May 26, 2024 (CLICK TO VIEW)

  • Monoclonal Gammopathy of Undetermined Significance
  • Multiple myeloma and minimal residual disease
  • Multiple myeloma and chimeric antigen receptor-T cell therapy
  • Relapsed/refractory large B‐cell lymphoma

News of the Week – May 19, 2024 (CLICK TO VIEW)

  • Mature T- and NK-cell neoplasms
  • Acute lymphoblastic leukemia
  • Acute myeloid leukemia
  • Acute lymphoblastic leukemia
  • Multiple myeloma

News of the Week – May 12, 2024 (CLICK TO VIEW)

  • Measurable residual disease in multiple myeloma
  • “Minimal” residual disease in multiple myeloma
  • Untreated mantle cell lymphoma
  • Immune thrombotic thrombocytopenia purpura treatment
  • Relapsed or refractory primary mediastinal large B-cell lymphoma
  • Relapsed or refractory marginal zone lymphoma

News of the Week – May 5, 2024 (CLICK TO VIEW)

  • Chimeric antigen receptor (CAR) T-cells, bispecific antibodies (BsAbs), and relapsed and refractory large B-cell lymphoma (R/R LBCL)
  • Chimeric antigen receptor (CAR) T-cells and Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
  • Myelodysplastic syndromes (MDS)
  • Acute myeloid leukemia (AML)
  • Monoclonal B-cell lymphocytosis (MBL)

News of the Week – April 28, 2024 (CLICK TO VIEW)

  • Hemoglobinopathies & gene edition
  • Chimeric antigen receptor T cell (CAR T) therapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT)
  • Primary sinonasal diffuse large B-cell lymphoma (PSDLBCL)
  • Polycythemia vera (PV)
  • Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) syndrome
  • Post-transplant lymphoproliferative disorder (PTLPD)

News of the Week – April 21, 2024 (CLICK TO VIEW)

  • Chronic graft-vs-host disease (cGVHD)
  • Immune effector cell therapy-associated cytokine release syndrome
  • Multiple myeloma (MM) and chimeric antigen receptor T (CAR T) cell therapy
  • Non-Hodgkin lymphoma (NHL) and bispecific antibodies (BsAb)
  • Diffuse large B-cell lymphoma (DLBCL)

News of the Week – April 14, 2024 (CLICK TO VIEW)

  • Acute myeloid leukemia (AML)
  • Infections in secondary hypogammaglobulinemia in hematological malignancies.
  • Relapsed/refractory multiple myeloma (RRMM)
  • Cardiotoxicity and non-Hodgkin lymphoma (NHL)
  • Triple negative-primary myelofibrosis (TN-PMF)
  • Mature T-cell lymphomas (TCL) and chimeric antigen receptor T (CAR T) therapies

News of the Week – April 7, 2024 (CLICK TO VIEW)

  • AL amyloidosis
  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Extranodal natural killer/T cell lymphoma (ENKTL)
  • Chimeric antigen receptor T (CAR T) therapies
  • Acute myeloid leukemia (AML)

News of the Week – March 31, 2024 (CLICK TO VIEW)

  • Primary immune thrombocytopenia (ITP) therapies
  • Primary testicular lymphoma (pTL)
  • Hemophilia B
  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Multiple myeloma (MM)
  • Hematopoietic cell transplantation (HCT) and cellular therapies.

News of the Week – March 24, 2024 (CLICK TO VIEW)

  • Chimeric antigen receptor T cell (CAR-T) therapies
  • Acute myeloid leukemia (AML)
  • B-cell malignancies
  • Central nervous system (CNS) B-cell lymphoma
  • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)
  • Myelofibrosis

News of the Week – March 17, 2024 (CLICK TO VIEW)

  • Paroxysmal nocturnal hemoglobinuria (PNH)
  • Acute myeloid leukemia (AML)
  • Chronic myeloid leukemia (CML)
  • Autoimmune hemolytic anemia (AIHA)

News of the Week – March 10, 2024 (CLICK TO VIEW)

  • Multiple myeloma (MM) – DREAMM-8 phase III trial (NCT04484623)
  • T-prolymphocytic leukemia (T-PLL) – phase II study (NCT03873493)
  • High-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) – safety and efficacy of prophylactic maintenance therapy with venetoclax and azacitidine
  • Aplastic anemia (AA) – SOAR (NCT02998645)
  • Chimeric antigen receptor (CAR)-T-cell therapy – Rare secondary T-cell lymphomas after CD19- and BCMA-directed CAR-T-cell therapy